Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1512060 | 0.84 | DPP4 (0.35) | MEN1KMT2AHTTDPP4TDP1 | |
| SCHEMBL29419387 | 0.84 | DPP4 (0.35) | MEN1KMT2AHTTDPP4TDP1 | |
| Hydrochloric Acid SCHEMBL1512064 | 0.82 | DPP4 (0.34) | MEN1KMT2AHTTDPP4TDP1 | |
| SCHEMBL9178364 | 0.80 | KDM4E (0.40) | MEN1KMT2ATDP1ADORA2AADORA1 | |
| SCHEMBL9192133 | 0.80 | TDP1 (0.35) | MEN1KMT2AHTTDPP4TDP1 | |
| SCHEMBL5261298 | 0.79 | TDP1 (0.42) | MEN1KMT2ADPP4TDP1ADORA2A | |
| SCHEMBL2072565 | 0.79 | ALDH1A1 (0.47) | MEN1KMT2AHTTTDP1LMNA | |
| SCHEMBL24862134 | 0.76 | GOT1 (0.32) | MEN1KMT2AHTTDPP4CHUK | |
| SCHEMBL11061973 | 0.74 | GLP1R (0.44) | DPP4ADORA2AADORA1LMNA | |
| SCHEMBL22039133 | 0.74 | PTPN1 (0.38) | MEN1KMT2ADPP4ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 445 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912457-A | Pyrimidine triazole compound as well as preparation method and application thereof | 郑州大学 | 2025-05-02 | — | — | CN | claimed |
| CN-106432330-B | The midbody compound and its preparation method and application of LB80380 drug | 天津科伦药物研究有限公司 | 2019-02-01 | — | — | CN | claimed |
| EP-3226861-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2017-10-11 | — | — | EP | claimed |
| WO-2016087665-A2 | COMPOUNDS FOR TREATING CYSTIC FIBROSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-09 | — | — | WO | claimed |
| EP-2680847-A1 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF | Ustav Organicke Chemie A Biochemie Akademie Ved Cr, v.v.i. (CZ) | 2014-01-08 | — | — | EP | claimed |
| US-20130324566-A1 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF | USTAV EXPERIMENTALNI MEDICINY AKADEMIE VED CR, v.v.i. (CZ) | 2013-12-05 | — | — | US | claimed |
| WO-2012116666-A1 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF | USTAV ORGANICKE CHEMIE A BIOCHEMIE AKADEMIE VED CR, v.v.i. (CZ) | 2012-09-07 | — | — | WO | claimed |
| CN-102098918-A | Bioactive compounds for treatment of cancer and neurodegenerative diseases | PONIARD PHARMACEUTICALS INC | 2011-06-15 | — | — | CN | claimed |
| EP-2273882-A1 | BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES | Poniard Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| CN-101130542-B | Synthesis of antiviral nucleoside analogues | JIANGSU CHIA TAI TIANQING PHAR | 2010-08-04 | — | — | CN | claimed |
| EP-0741710-B1 | CHLOROPYRIMIDINE INTERMEDIATES | WELLCOME FOUND (GB) | 2000-05-10 | — | — | EP | claimed |
| US-5917042-A | Process for the preparation of 2,5-diamino-4,6-dichloropyrimidine | GLAXO WELLCOME INC. (US) | 1999-06-29 | — | — | US | claimed |
| EP-0816344-A1 | Process for the production of 2,5-diamino-4,6-dichloropyrimidine | LONZA AG (CH) | 1998-01-07 | — | — | EP | claimed |
| US-5693800-A | N-(2-amino-4,6-dichloropyrimidine-5-yl) formamide and a process for its preparation | LONZA AG (CH) | 1997-12-02 | — | — | US | claimed |
| EP-0552758-B1 | N-5-protected 2,5-diamino-4,6-dichloropyrimidines and process for their preparation | LONZA AG (CH) | 1997-06-11 | — | — | EP | claimed |
| EP-0684236-A2 | N-(2-Amino-4,6-dichloropyrimidin-5-yl)formamide and process for its production | LONZA AG (CH) | 1995-11-29 | — | — | EP | claimed |
| WO-1995021161-A1 | CHLOROPYRIMIDE INTERMEDIATES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-08-10 | — | — | WO | claimed |
| US-5294710-A | N-5-protected 2,5-diamino-4,6-dichloropyrimidines and process for their production | LONZA LTD. (CH) | 1994-03-15 | — | — | US | claimed |
| CN-1077193-A | N-5 position-protected 2,5-diamino-4,6-dichloro pyrimidine and production method thereof | LONZA AG (CH) | 1993-10-13 | — | — | CN | claimed |
| EP-0552758-A1 | N-5-protected 2,5-diamino-4,6-dichloropyrimidines and process for their preparation | LONZA AG (CH) | 1993-07-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324566-A1 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF | PTGIS, PTGS2, PTGES2 | MEN1 4147/4885KMT2A 4035/4885HTT 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.